{
    "data": [
        {
            "id": 2993195,
            "title": "AM Best Upgrades Outlook on ICICI Lombard, Affirms Key Credit Ratings",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>ICICI Lombard General Insurance Co. Ltd. ( <a data-ticker=\"IN:ICICIGI\" href=\"https://www.tipranks.com/stocks/in:icicigi\">(IN:ICICIGI)</a> ) has shared an update.</p>\n<p></p>\n<p></p><p>ICICI Lombard has announced that global rating agency AM Best has revised its outlook on the company’s ratings to positive from stable, while affirming its Financial Strength Rating at B++ (Good) and its Long-Term Issuer Credit Rating at “bbb+” (Good). AM Best has also affirmed the company’s India National Scale Rating of aaa.IN (Exceptional) with a stable outlook, reflecting a very strong balance sheet, strong operating performance, a neutral business profile and appropriate enterprise risk management.</p>\n<p>The revision in outlook to positive signals growing confidence in ICICI Lombard’s capital strength and earnings profile, which may enhance its credibility with investors, regulators and policyholders. The affirmed ratings and supportive commentary on risk management underscore the company’s solid position in India’s general insurance market and could support its competitive standing and future growth initiatives.</p>\n<p><b><u>More about ICICI Lombard General Insurance Co. Ltd.</u></b></p>\n<p>ICICI Lombard General Insurance Company Limited is a leading Indian non-life insurer, offering a broad range of general insurance products and services. The company operates in the domestic market under the oversight of the Insurance Regulatory and Development Authority of India, serving retail and corporate customers across multiple segments.</p>\n<p><b>Average Trading Volume:</b> 18,970</p>\n<p><b>Technical Sentiment Signal:</b> Strong Buy</p>\n<p><b>Current Market Cap:</b> 948.4B INR</p>\n<p></p>\n<p></p><p>Find detailed analytics on ICICIGI stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/in:icicigi\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1895847139-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/am-best-upgrades-outlook-on-icici-lombard-affirms-key-credit-ratings",
            "author": "TipRanks India Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 13:05:49",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2992954,
            "title": "Dynamite Blockchain Changes Auditor in Routine Transition",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>Cryptoblox Technologies ( <a data-ticker=\"TSE:KAS\" href=\"https://www.tipranks.com/stocks/tse:kas\">(TSE:KAS)</a> ) has shared an update.</p>\n<p></p>\n<p></p><p>Dynamite Blockchain Corp., a Vancouver-based blockchain technology and infrastructure firm, operates a vertically integrated ecosystem built around utility-driven digital asset holdings, complemented by products and services designed to enhance token utility and real-world monetization for shareholders. The company emphasizes ownership of rare digital assets paired with an investment model that integrates utility generation into its core business.</p>\n<p>The company has appointed Davidson and Company LLP as its new auditor, replacing SRCO Professional Corporation effective February 19, 2026, following approval by its board and audit committee. Dynamite reported no reservations, modified audit opinions or reportable events associated with the transition, signaling a routine change in auditors that is unlikely to indicate operational or financial concerns for stakeholders.</p>\n<p><b><u>More about Cryptoblox Technologies</u></b></p>\n<p>Dynamite Blockchain Corp. is a Vancouver-based blockchain technology and infrastructure company executing a vertically integrated Blockchain Ecosystem Strategy across Holdings, Products and Services divisions. Its model centers on acquiring utility-driven, scarce digital tokens and developing compatible products and services to enhance real-world adoption, monetization and embedded utility for shareholders.</p>\n<p><b>Average Trading Volume:</b> 433,905</p>\n<p><b>Technical Sentiment Signal:</b> Strong Sell</p>\n<p><b>Current Market Cap:</b> C$15.46M</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_410606110-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/dynamite-blockchain-changes-auditor-in-routine-transition",
            "author": "TipRanks Canadian Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 11:32:22",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2992890,
            "title": "Canamera to Raise Up to C$4 Million for Rare Earth and Uranium Exploration",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>Canamera Energy Metals Corp ( <a data-ticker=\"TSE:EMET\" href=\"https://www.tipranks.com/stocks/tse:emet\">(TSE:EMET)</a> ) has provided an announcement.</p>\n<p></p>\n<p></p><p>Canamera Energy Metals Corp. plans to raise up to C$2.5 million through a non-brokered private placement under the Listed Issuer Financing Exemption, offering 4,545,454 units at C$0.55 each, with each unit comprising one common share and a half warrant exercisable at C$0.65. The company also launched a concurrent non-brokered private placement of up to 2,272,727 flow-through units at C$0.66 to raise up to C$1.5 million for Canadian exploration expenses, with total proceeds earmarked to advance its mineral projects, maintain property obligations and fund working capital and investor relations, potentially accelerating exploration across its North and South American portfolio.</p>\n<p>The most recent analyst rating on <a data-ticker=\"TSE:EMET\" href=\"https://www.tipranks.com/stocks/tse:emet\">(TSE:EMET)</a> stock is a Hold with a C$0.59 price target. To see the full list of analyst forecasts on Canamera Energy Metals Corp stock, see the TSE:EMET <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/tse:emet/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on TSE:EMET Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, TSE:EMET is a Neutral.</p>\n<p>The score is primarily held down by weak financial performance (no revenue, ongoing losses, and continued cash burn), partially offset by a low-debt balance sheet. Technicals are mixed with some longer-term trend support but softer near-term momentum, while valuation is constrained by negative earnings and no indicated dividend yield.</p>\n<p>To see Spark’s full report on TSE:EMET stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/tse:emet/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Canamera Energy Metals Corp</u></b></p>\n<p>Canamera Energy Metals Corp. is a critical and rare earth metals exploration company focused on building a diversified portfolio of district-scale projects across the Americas. Its assets include rare earth, niobium and uranium projects in Ontario, Colorado, British Columbia and Wyoming, as well as rare earth element projects in Brazil, targeting underexplored regions with supportive jurisdictions.</p>\n<p><b>Average Trading Volume:</b> 653,885</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> C$43.15M</p>\n<p></p>\n<p></p><p>See more insights into EMET stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/tse:emet\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1388100275-3-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/canamera-to-raise-up-to-c4-million-for-rare-earth-and-uranium-exploration",
            "author": "TipRanks Canadian Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 11:08:47",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2992799,
            "title": "Cannabist Company Wins New Extension on Noteholder Forbearance",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>An update from Cannabist Company Holdings ( <a data-ticker=\"TSE:CBST\" href=\"https://www.tipranks.com/stocks/tse:cbst\">(TSE:CBST)</a> ) is now available.</p>\n<p></p>\n<p></p><p>The Cannabist Company said an ad hoc group of holders of its 9.25% Senior Secured Notes and 9.00% Senior Secured Convertible Notes, both due December 31, 2028, has agreed to further extend a forbearance arrangement. The noteholders will refrain from exercising their rights and remedies under the governing indenture and applicable law until March 6, 2026, giving the cannabis operator additional time to manage its capital structure and negotiate with creditors.</p>\n<p>The extension of forbearance provides short-term breathing room as The Cannabist Company navigates its debt obligations, which are significant for a sector still constrained by federal prohibition and limited banking access. The added time may help stabilize operations and preserve value for stakeholders while the company evaluates strategic and financial options in a challenging U.S. cannabis financing environment.</p>\n<p>The most recent analyst rating on <a data-ticker=\"TSE:CBST\" href=\"https://www.tipranks.com/stocks/tse:cbst\">(TSE:CBST)</a> stock is a Hold with a C$0.55 price target. To see the full list of analyst forecasts on Cannabist Company Holdings stock, see the TSE:CBST <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/tse:cbst/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on TSE:CBST Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, TSE:CBST is a Underperform.</p>\n<p>Cannabist Company Holdings is facing severe financial difficulties, with declining revenues, high leverage, and negative equity. The technical analysis indicates an overbought condition without clear momentum, and the valuation reflects unprofitability. These factors contribute to a low overall stock score.</p>\n<p>To see Spark’s full report on TSE:CBST stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/tse:cbst/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Cannabist Company Holdings</u></b></p>\n<p>The Cannabist Company, formerly Columbia Care, is a U.S. multi-state cannabis operator with licenses in 11 jurisdictions. It runs 69 facilities, including 54 dispensaries and 15 cultivation and manufacturing sites, serving both medical and adult-use markets with branded products across flower, edibles, oils and tablets.</p>\n<p><b>Technical Sentiment Signal:</b> Sell</p>\n<p><b>Current Market Cap:</b> C$227.8M</p>\n<p></p>\n<p></p><p>For a thorough assessment of CBST stock, go to <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/tse:cbst\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1264051801-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/cannabist-company-wins-new-extension-on-noteholder-forbearance",
            "author": "TipRanks Canadian Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 10:33:05",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2992744,
            "title": "Empress Royalty Posts Record 2025 Results and Targets Higher GEO Output in 2026",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>Empress Royalty ( <a data-ticker=\"TSE:EMPR\" href=\"https://www.tipranks.com/stocks/tse:empr\">(TSE:EMPR)</a> ) has issued an announcement.</p>\n<p></p>\n<p></p><p>Empress Royalty reported a record year in 2025, doubling revenue and delivering US$17.2 million in royalty and streaming income, US$12.1 million in gross profit, and US$7.4 million in net income, alongside positive operating cash flow of US$3.7 million and adjusted EBITDA of US$13.9 million. Management highlighted the strength and high-margin profile of its portfolio and issued 2026 guidance of 7,045 to 7,430 attributable gold equivalent ounces, signaling expectations for further growth supported by ongoing production from key assets and stable or improving gold and silver markets.</p>\n<p>The company emphasized its disciplined capital allocation and improved balance sheet, positioning it to redeploy capital into selective, value-accretive royalty and streaming opportunities. By focusing on attributable gold equivalent ounces as a core performance metric, Empress aims to demonstrate diversified exposure to gold and silver production while reducing reliance on short-term price volatility and reinforcing its competitive position among precious metals royalty players.</p>\n<p>The most recent analyst rating on <a data-ticker=\"TSE:EMPR\" href=\"https://www.tipranks.com/stocks/tse:empr\">(TSE:EMPR)</a> stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Empress Royalty stock, see the TSE:EMPR <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/tse:empr/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on TSE:EMPR Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, TSE:EMPR is a Neutral.</p>\n<p>The score is primarily supported by improved financial performance (strong margins, solid cash conversion, and low leverage), but tempered by concerns about consistency given the short track record of sustained profitability. Technical signals are currently soft and valuation looks relatively rich on P/E with no dividend support, while corporate updates are generally constructive.</p>\n<p>To see Spark’s full report on TSE:EMPR stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/tse:empr/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Empress Royalty</u></b></p>\n<p>Empress Royalty Corp. is a Vancouver-based precious metals royalty and streaming company focused on gold and silver. By investing in royalties and streams on producing and near-producing mines, it aims to provide shareholders with leveraged exposure to metal prices and high-margin cash flow without taking on direct operating risk.</p>\n<p><b>Average Trading Volume:</b> 572,098</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> C$158.2M</p>\n<p></p>\n<p></p><p>See more insights into EMPR stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/tse:empr\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2003804756-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/empress-royalty-posts-record-2025-results-and-targets-higher-geo-output-in-2026",
            "author": "TipRanks Canadian Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 10:12:37",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2992421,
            "title": "Taiga Building Products Hit by U.S. Impairment as 2025 Profit Declines",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>The latest update is out from Avarga Limited ( <a data-ticker=\"SG:X5N\" href=\"https://www.tipranks.com/stocks/sg:x5n\">(SG:X5N)</a> ).</p>\n<p></p>\n<p></p><p>Taiga Building Products reported that fourth-quarter 2025 net sales fell 8% to $359.6 million amid lower lumber prices and reduced volumes, though gross margin dollars were stable and margin percentage improved on lower product costs. The quarter swung to a net loss of $9.1 million from a $6.6 million profit after a $20.5 million non-cash impairment of goodwill and intangibles at its Washington State subsidiary, reflecting weaker U.S. housing market conditions.</p>\n<p>For full-year 2025, net sales were essentially flat at $1.63 billion, but gross margin rose modestly to $176.4 million due to cheaper product costs despite softer pricing and volumes. Annual net earnings dropped to $28.6 million from $47.6 million and EBITDA declined to $56.7 million from $79.8 million, as the U.S. unit’s impairment weighed on profitability even as management signaled confidence in a longer-term recovery in U.S. housing and renovation markets.</p>\n<p><b><u>More about Avarga Limited</u></b></p>\n<p>Taiga Building Products Ltd. is a North American distributor of lumber and building materials, supplying a range of wood products to construction and renovation markets. The company operates across Canada and the U.S., with exposure to housing and repair-and-remodel activity, including a subsidiary in Washington State that serves regional demand.</p>\n<p><b>Average Trading Volume:</b> 6,062</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> S$126.1M</p>\n<p></p>\n<p></p><p>Learn more about X5N stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/sg:x5n\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Industrials-2-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/taiga-building-products-hit-by-u-s-impairment-as-2025-profit-declines",
            "author": "TipRanks Singapore Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 09:12:14",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2992293,
            "title": "Churchill Downs Earnings Call Highlights Derby-Fueled Growth",
            "description": "<html><head></head><body><p>Churchill Downs (<a data-ticker=\"CHDN\" href=\"https://www.tipranks.com/stocks/chdn\">(CHDN)</a>) has held its Q4 earnings call. Read on for the main highlights of the call. </p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Churchill Downs’ latest earnings call struck an upbeat tone as management highlighted record net revenue, record adjusted EBITDA and a powerful $700 million in free cash flow for 2025. While earnings came in just shy of last year’s peak and some regional pressures surfaced, executives framed these as manageable headwinds against a strong growth and deleveraging story into 2026.</p>\n<h2>Record Revenue and Adjusted EBITDA Streak Extends</h2>\n<p>Churchill Downs reported record net revenue and record adjusted EBITDA for 2025, including record fourth-quarter figures. Excluding the pandemic year, this marks nine consecutive years of record top-line and adjusted EBITDA performance, reinforcing the company’s ability to compound growth through both its racing and gaming platforms.</p>\n<h2>Kentucky Derby and Derby Week Powerhouse</h2>\n<p>The Kentucky Derby franchise remained the crown jewel, delivering record handle for the race, Derby Day program and Derby Week overall. The company also posted the highest television ratings in nearly four decades and expects the 2026 Derby to generate an additional $15 million to $20 million of incremental adjusted EBITDA.</p>\n<h2>Robust Free Cash Flow and Shareholder Returns</h2>\n<p>Free cash flow surged to a record $700 million, or $9.75 per share, underscoring the cash-generative nature of the portfolio. Management deployed this strength by repurchasing over 4.2 million shares, returning more than $456 million to shareholders through buybacks and dividends, and extending its streak of annual dividend-per-share increases to 15 years.</p>\n<h2>HRM Footprint Expansion and New Projects</h2>\n<p>The company continued to build out its historical racing machine network with new openings in Owensboro, Marshall Yards and Roseshire, alongside progress on The Rose project. It also announced a major $180 million to $200 million investment in the Rockingham Grand Casino in Salem, New Hampshire, signaling confidence in long-term regional demand.</p>\n<h2>Wagering Services Growth Led by Exacta</h2>\n<p>The Wagering Services and Solutions segment posted a 7% increase in adjusted EBITDA for 2025, driven primarily by growth in Exacta. Management highlighted ongoing momentum in business-to-business deployments, adding new customers in Kansas and Alabama that broaden the distribution of its wagering technology.</p>\n<h2>Electronic Table Games as a New Growth Avenue</h2>\n<p>Churchill Downs secured regulatory approval in Kentucky and launched roulette electronic table games in early February, opening a new product channel. While the ETG rollout contributed nothing to 2025 results, the company views the early-stage deployment and potential additions like craps and blackjack as a meaningful long-term earnings lever.</p>\n<h2>Churchill Downs Racetrack Upgrades and Capacity Gains</h2>\n<p>At the flagship racetrack, the company completed renovations including the starting gate Pavilion for roughly 8,100 guests and a redesigned Paddock. Ongoing work on the Mansion and Finish Line Suites remains on time and on budget, and the upcoming Victory Run project will add about 1,400 seats, a 22% capacity boost in that premium area.</p>\n<h2>Disciplined Capital Allocation and Leverage Management</h2>\n<p>Maintenance capital expenditure totaled $70 million in 2025 with expectations rising to $90 million to $110 million in 2026, while project capex was $205 million and is guided to $180 million to $220 million next year. Bank covenant net leverage stood at 4.1x at year-end 2025, and management anticipates this ratio falling below 4.0x during 2026 as strong cash flow supports further balance sheet improvement.</p>\n<h2>Earnings Below Peak Amid Tough Comparisons</h2>\n<p>Despite record revenue and adjusted EBITDA, management acknowledged that overall earnings landed slightly below the prior year’s record level. The company cited challenging year-over-year comparisons and pockets of economic uncertainty earlier in 2025, but stressed that core demand trends and project execution remain on track.</p>\n<h2>Tariff Volatility and Sales-Cycle Disruptions</h2>\n<p>Executives flagged that <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/stocks-hurt-by-trump-tariffs\">tariff</a>-related volatility and broader macro uncertainty disrupted the sales process for certain events late in the selling cycle. This timing issue weighed on revenue cadence earlier in 2025, but was portrayed as a transitory factor rather than a structural change in demand.</p>\n<h2>Regional Gaming Margins Face Mild Pressure</h2>\n<p>Same-store wholly owned casino margins, excluding racing, slipped by 0.8 percentage points versus 2024, with softness concentrated in Mississippi. Management linked this modest compression to local market challenges and emphasized that the overall regional portfolio remains resilient and profitable.</p>\n<h2>Weather and Local Issues Temporarily Impact Operations</h2>\n<p>Significant January weather events and localized disruptions, including roadwork and curfews in Mississippi plus adverse conditions in December, created short-term revenue headwinds. The company noted that underlying customer demand held up well once these temporary obstacles eased.</p>\n<h2>Deliberate ETG Rollout Strategy</h2>\n<p>The ETG initiative remains in a measured ramp-up phase, starting with roulette and expanding only as products prove themselves with customers and regulators. Management stressed that ETGs provided no incremental benefit to 2025 results and are being managed as a multi-year earnings opportunity rather than a quick fix.</p>\n<h2>Regulatory and Legislative Uncertainty</h2>\n<p>The company continues to monitor legislative developments around iGaming and other competitive shifts, calling out Virginia discussions as a potential risk to its operations there. While management views iGaming as unfavorable for its Virginia properties, it framed this as an ongoing policy watch item rather than an immediate financial shock.</p>\n<h2>Guidance Signals Confident 2026 Outlook</h2>\n<p>Looking ahead, Churchill Downs expects the 2026 Kentucky Derby to contribute $15 million to $20 million of incremental adjusted EBITDA as Derby Week expands to seven live race dates across eight days with attendance around 75,000 and pacing already ahead of prior years. Project capex is projected at $180 million to $220 million, maintenance capex at $90 million to $110 million and leverage is expected to drop below 4.0x, supported by continued strong cash generation after 2025’s $700 million free cash flow.</p>\n<p>Overall, the earnings call painted the picture of a company leaning into its marquee Derby brand, expanding HRM and ETG platforms and returning significant capital while keeping leverage in check. Short-term margin and macro bumps were acknowledged but framed as manageable, leaving investors with a narrative centered on sustained cash flow, disciplined investment and a constructive growth trajectory into 2026 and beyond.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Cylical-5-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/churchill-downs-earnings-call-highlights-derby-fueled-growth",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 08:29:51",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2992275,
            "title": "Chemtrade Logistics Signals Record Year, Choppy 2026 Ahead",
            "description": "<html><head></head><body><p>Chemtrade Logistcs (($TSE:CHE.UN)) has held its Q4 earnings call. Read on for the main highlights of the call. </p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Chemtrade Logistics’ latest earnings call painted a broadly upbeat picture, with 2025 marked as a record year despite some clear near‑term headwinds. Management highlighted improved reliability across key assets, strong water chemicals margins, and better reporting transparency, while also cautioning about raw material cost spikes, weaker caustic prices, and heavier 2026 maintenance outages.</p>\n<h2>Record 2025 Performance Sets a High Bar</h2>\n<p>Chemtrade reported 2025 as a record year, underlining strong execution across its portfolio and thanking employees for driving the performance. The tone suggested that, even with some market and cost volatility, the company exited the year in a stronger operational and financial position than before.</p>\n<h2>Water Chemicals Delivers Standout Margins</h2>\n<p>The specialty water chemicals (SWC) segment posted EBITDA margins of about 23% in 2025, underscoring its role as a key profit engine. Management stressed that these margins were achieved despite elevated input costs, reinforcing the resilience and pricing power of the water chemicals franchise.</p>\n<h2>Regen Acid Reliability on a Multi‑Year Uptrend</h2>\n<p>The regen acid business continued its steady year‑over‑year improvement in both performance and reliability, building on a positive multi‑year trend. Executives emphasized ongoing incremental gains, implying more stable production, fewer disruptions, and better earnings visibility from this segment.</p>\n<h2>Cairo and Tulsa Upgrades Target Quality and Growth</h2>\n<p>Chemtrade’s Cairo facility is progressing well through customer approval processes, with many samples in the field and a sales volume ramp expected in the second half of 2026. In parallel, Tulsa has received targeted upgrades leveraging Cairo learnings, aimed at higher product quality and potential qualification for more advanced customer applications.</p>\n<h2>New Segment Reporting to Sharpen Visibility</h2>\n<p>Starting with first‑quarter 2026 results, Chemtrade will report water chemicals as a standalone segment, improving transparency into revenue, EBITDA, and margins by line of business. Management framed this as a key step for investors and analysts to better model performance drivers and understand the contribution of SWC.</p>\n<h2>CapEx and LTIP Framework Clarified for Investors</h2>\n<p>The company outlined a sustaining capital spend of roughly $120 million to $130 million per year, providing a clearer baseline for long‑term modeling. Growth CapEx is expected around $35 million to $50 million annually, excluding any potential North Vancouver rezoning‑related spending, with long‑term incentive costs guided to a $22 million to $28 million range.</p>\n<h2>Sulphur Cost Spike Squeezes Margin Percentages</h2>\n<p>A sharp escalation in sulphur costs during 2025 weighed on reported SWC margin percentages, even as Chemtrade worked to protect absolute EBITDA levels. Management noted that when raw material prices spike, percentage margins naturally compress, hinting that margin optics should improve if sulphur prices normalize.</p>\n<h2>Caustic Soda Weakness Delays Price Recovery</h2>\n<p>Spot caustic soda prices started 2026 below the roughly US$450 per ton level assumed in guidance, reflecting temporary oversupply, notably from China, and softer demand. Chemtrade now expects a more meaningful price recovery only in the second half of 2026, pushing some earnings upside later in the year.</p>\n<h2>Heavier 2026 Turnarounds to Hit Q2 Results</h2>\n<p>The company flagged a heavier‑than‑usual turnaround schedule in 2026 for the SWC business, with outages aligning to customer maintenance cycles and creating lumpier production. A key turnaround at North in the second quarter is expected to weigh on Q2 results, making quarterly timing especially important for investors.</p>\n<h2>Merchant Acid Pricing Normalizing After Windfall</h2>\n<p>Merchant acid benefited in 2025 from exceptional spot opportunities triggered by competitor outages, boosting realized pricing. Management expects 2026 merchant acid prices to be modestly lower than last year, reverting toward more typical levels as supply conditions normalize.</p>\n<h2>Polytec Acquisition Causes Audit Timing Hiccup</h2>\n<p>Fourth‑quarter and full‑year figures were released on an unaudited basis because the late‑November closing of the Polytec acquisition added complexity and delayed audit completion. While framed as a one‑time timing issue, the move highlighted how M&amp;A can temporarily disrupt reporting schedules.</p>\n<h2>Variable Compensation Adds Noise to Corporate Costs</h2>\n<p>The strong unit price performance in 2025 drove long‑term incentive expenses to the high end of the guidance range, lifting corporate costs for the year. Management suggested that underlying program costs should be similar in 2026, but reminded investors that LTIP remains variable and can swing corporate overhead.</p>\n<h2>Guidance Points to Back‑Half Weighted 2026</h2>\n<p>For 2026, Chemtrade’s guidance assumes caustic soda prices around US$450 per ton over the year, though actual spot levels started weaker and are only expected to rebound in the second half. Sustaining CapEx is pegged at about $120 million to $130 million, growth CapEx at roughly $35 million to $55 million, LTIP at $22 million to $28 million, and earnings seasonality tilted toward stronger Q2–Q3, with Cairo’s sales ramp and heavier SWC turnarounds shaping the quarterly profile.</p>\n<p>Chemtrade’s earnings call blended confidence in record 2025 execution with realism about near‑term cost and pricing pressures. With key assets performing better, targeted growth projects advancing, and clearer capital and reporting frameworks, management is positioning the company for a stronger second half of 2026, even as investors prepare for a choppier first half and heavier maintenance year.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2135555081-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/chemtrade-logistics-signals-record-year-choppy-2026-ahead",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 08:26:27",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2992241,
            "title": "Intellia Therapeutics Eyes 2026 Pivotal CRISPR Milestone",
            "description": "<html><head></head><body><p>Intellia Therapeutics Inc (<a data-ticker=\"NTLA\" href=\"https://www.tipranks.com/stocks/ntla\">(NTLA)</a>) has held its Q4 earnings call. Read on for the main highlights of the call. </p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Intellia Therapeutics’ latest earnings call struck a cautiously optimistic tone, blending clinical momentum and strengthening financial discipline with serious safety and regulatory overhangs. Management leaned into the potential of lonvo-z as a first-in-class in vivo CRISPR therapy while acknowledging that the unresolved FDA hold on the key cardiomyopathy program continues to cap investor confidence.</p>\n<h2>Lonvo-z Phase 3 on Track for First Pivotal CRISPR Readout</h2>\n<p>Intellia confirmed that the HAELO Phase 3 trial of lonvo-z in hereditary angioedema is fully enrolled, with 80 patients recruited in roughly nine months. Top-line data are expected by mid-2026, and the company is targeting a BLA filing in the second half of 2026, positioning lonvo-z for the first pivotal readout of an in vivo CRISPR gene-editing therapy.</p>\n<h2>Robust Patient and Physician Appetite for Gene Editing in HAE</h2>\n<p>Survey work suggests a receptive U.S. market for lonvo-z if the data hold up, with 99% of patients indicating at least some willingness to take a gene-editing therapy and nearly two-thirds reporting they are extremely or very likely to do so. Among 151 U.S. physicians managing more than 4,000 patients, 92% said they could identify candidates and estimated they would prescribe lonvo-z to roughly 2,200, or about 54% of their treated population.</p>\n<h2>Durable Efficacy Signals Support Lonvo-z’s One-Time Treatment Thesis</h2>\n<p>Management highlighted durability data from early-phase studies, noting up to three years of follow-up without evidence of waning serum kallikrein or TTR suppression. A pooled analysis showed that 76% of patients at least one year beyond a 50 mg dose were free of attacks and off ongoing therapy for 12 months or more, a stark contrast with current prophylactics, where roughly 20% of patients remain attack-free.</p>\n<h2>Q4 2025 Numbers Show Improving P&amp;L Discipline</h2>\n<p>On the financial front, Intellia delivered stronger fourth-quarter metrics, with collaboration revenue rising to $23.0 million from $12.9 million, a gain of about 78% year over year. R&amp;D spending fell to $88.7 million from $116.9 million, helping narrow the quarterly net loss to $95.8 million from $128.9 million, a sign of tightening cost control as key trials mature.</p>\n<h2>Cash Runway Extends into 2027 but Headroom Has Shrunk</h2>\n<p>The company closed 2025 with $605.1 million in cash, cash equivalents and marketable securities, down from $861.7 million a year earlier, a roughly 30% decline. Management believes this balance is sufficient to fund operations into the second half of 2027 and carry Intellia through major lonvo-z milestones, while commercial manufacturing, field teams and payer outreach for a possible launch are already largely in place.</p>\n<h2>MAGNITUDE-2 ATTR Polyneuropathy Program Back in Motion</h2>\n<p>Regulatory fortunes were mixed, with the FDA lifting the clinical hold on MAGNITUDE-2 for ATTR polyneuropathy in late January after agreeing on tighter safety measures. The study now includes additional early post-dose liver testing, a short-course steroid protocol for liver function spikes and refined screening, and its enrollment target has risen to about 60 patients, with 47 already recruited heading into an expected completion in the second half of 2026.</p>\n<h2>Cardiomyopathy Trial Remains Frozen Under FDA Scrutiny</h2>\n<p>By contrast, MAGNITUDE in ATTR cardiomyopathy remains on full clinical hold after serious liver enzyme and bilirubin elevations in one patient, halting a trial that had already enrolled more than 650 participants, above its original 550-patient plan. Intellia is in ongoing dialogue with regulators and has proposed similar risk-mitigation steps, but no green light has yet been granted, leaving the largest commercial opportunity in limbo.</p>\n<h2>Serious Adverse Event Clouds Safety Profile and Adds Risk</h2>\n<p>The safety narrative was dominated by a patient in MAGNITUDE who developed Grade 4 elevations in liver transaminases and bilirubin and later died from a ruptured duodenal ulcer, with causality to treatment unclear. While the company said such severe liver events occurred in less than 1% of patients and appear immune-mediated, the mechanism is not fully understood, introducing meaningful regulatory and pipeline risk.</p>\n<h2>Cash Burn and Operational Disruption Highlight Execution Challenges</h2>\n<p>The roughly 30% year-over-year drop in cash underscores the cost of building a first-wave CRISPR business despite the improved quarterly loss profile. Operationally, the October enrollment suspension in MAGNITUDE and MAGNITUDE-2, subsequent FDA pauses and protocol amendments have added complexity and time, even as MAGNITUDE-2 now resumes under tighter monitoring requirements.</p>\n<h2>Pipeline Read-Through and HAE Reproducibility Remain Open Questions</h2>\n<p>Management acknowledged that it cannot yet definitively determine whether the liver toxicity signal is unique to the TTR target or could emerge in other in vivo CRISPR programs, leaving investors with unanswered questions about broader platform risk. Executives also flagged that Phase 1/2 HAE data came largely from ex-U.S. patients while Phase 3 includes U.S. subjects with potentially different baseline characteristics, creating some risk around how well early efficacy will translate.</p>\n<h2>Forward-Looking Outlook: Pivotal 2026 Data and Launch Ambitions</h2>\n<p>Looking ahead, Intellia framed 2026 as a pivotal year, with HAELO Phase 3 top-line lonvo-z data expected by mid-year, a planned BLA submission in the second half and a potential 2027 commercial launch if results and regulators cooperate. The company aims to complete MAGNITUDE-2 enrollment in the second half of 2026 under new liver-monitoring and steroid protocols, while managing a cash runway into late 2027 and betting that strong patient and physician interest will translate into substantial uptake if lonvo-z reaches the market.</p>\n<p>Intellia’s call painted the picture of a high-upside but high-risk story, with lonvo-z nearing a watershed CRISPR readout that could redefine HAE treatment and the company’s valuation. Yet the unresolved cardiomyopathy hold, safety uncertainties and a shrinking cash cushion temper the bull case, leaving investors to weigh breakthrough potential against regulatory and execution hazards over the next 18 to 24 months.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1931544818-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/intellia-therapeutics-eyes-2026-pivotal-crispr-milestone",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 08:20:57",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2992229,
            "title": "Jamieson Wellness Earnings Call Signals Growth Momentum",
            "description": "<html><head></head><body><p>Jamieson Wellness (<a data-ticker=\"TSE:JWEL\" href=\"https://www.tipranks.com/stocks/tse:jwel\">(TSE:JWEL)</a>) has held its Q4 earnings call. Read on for the main highlights of the call. </p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Jamieson Wellness’ latest earnings call struck an upbeat tone, as management leaned on double-digit top-line growth, expanding margins and a standout performance in China to frame a story of durable momentum. While higher SG&amp;A, a drop in strategic partner revenue and a working-capital build weighed on reported results, executives argued that these investments are deliberate and manageable against strong underlying profitability.</p>\n<h2>Strong Consolidated and Branded Revenue Growth</h2>\n<p>Jamieson posted about 12% full-year consolidated revenue growth, with its core branded business advancing nearly 16%, underscoring the strength of its portfolio. In Q4, consolidated revenue rose 13.4% to $277.7 million, powered by Jamieson Brands’ 17.1% gain to $237.4 million and a 20.2% jump at Youtheory.</p>\n<h2>Geographic Diversification with China and International Outperformance</h2>\n<p>China remained the star, with full-year growth above 56% and Q4 up 43.9%, making the market a key growth engine. International revenue climbed 24% for the year and 39.2% in Q4, while Canada outpaced its home market with roughly 6% full-year growth and 5.5% growth in the quarter.</p>\n<h2>Gross Profit and Margin Expansion</h2>\n<p>Consolidated gross profit increased by $18.5 million in Q4 to $118.7 million, lifting consolidated gross margin by about 180 basis points and highlighting operating leverage. Jamieson Brands’ gross profit rose 19.7%, and normalized gross margin improved 90 basis points to 47.6%, helped by a richer branded mix and scale benefits in China.</p>\n<h2>Improved Profitability and Strong Adjusted Metrics</h2>\n<p>Adjusted profitability remained a bright spot, with Q4 adjusted EBITDA up 13.7% to an unchanged margin of 24.3%, showing that growth is not diluting earnings quality. Normalized earnings from operations rose 13.3% to $60.4 million, adjusted net earnings reached $38.5 million and adjusted diluted EPS came in at $0.90.</p>\n<h2>High-ROI China Execution and Consumer Conversion</h2>\n<p>Management highlighted China as a high-return investment story, citing performance marketing that is translating awareness into sales. Brand awareness to trial conversion jumped 57%, and trial to regular-buyer conversion climbed 81%, allowing Jamieson to grow roughly four times faster than the broader vitamins, minerals and supplements market.</p>\n<h2>Strong Cash Position and Shareholder Returns</h2>\n<p>The company ended the year with $126.6 million in cash and available facilities, giving it ample flexibility despite near-term working-capital pressures. Jamieson returned capital aggressively, repurchasing about 1.2 million shares for $37.9 million and paying roughly $37.2 million in dividends, with a further $0.23-per-share dividend declared.</p>\n<h2>Operational Improvements and Innovation Momentum</h2>\n<p>Operationally, Jamieson completed the rollout of a new SAP system across headquarters and three manufacturing sites, a key step for scaling efficiently. Innovation continued to focus on high-demand need states like immunity, sleep, stress and energy, with a “global-to-local” model speeding successful products into new markets and retailers.</p>\n<h2>Strategic Partners Revenue Decline</h2>\n<p>Strategic Partner revenues were a weak spot, declining 4.4% in Q4, or about $1.9 million, as volumes softened and customer onboarding was delayed amid trade and <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/stocks-hurt-by-trump-tariffs\">tariff</a> uncertainty. Segment gross profit fell 2.4%, underscoring some sensitivity to external policy and logistics factors.</p>\n<h2>Higher SG&amp;A and One-Time Due Diligence Costs</h2>\n<p>SG&amp;A jumped 20% in Q4, or $9.8 million, as Jamieson leaned into performance marketing, especially in China, and built out global infrastructure and variable compensation. The quarter also absorbed $2.7 million of legal and professional expenses linked to due diligence on an acquisition that ultimately failed to meet return thresholds.</p>\n<h2>Reported Operating Income Nearly Flat After Investments</h2>\n<p>Despite strong growth in revenue and gross profit, reported earnings from operations were essentially flat in Q4, slipping about 0.02% as spending ramped up. Management emphasized that on a normalized basis operating income still climbed, framing the gap as largely tied to deliberate brand-building and one-off deal costs.</p>\n<h2>Working Capital Build and Cash from Operations Pressure</h2>\n<p>Cash from operations fell to $31.9 million from $37.8 million a year earlier, but performance before working capital actually improved, reflecting underlying earnings strength. The drag came from an $18.8 million working-capital increase driven by higher inventory to cushion tariff risks and port congestion, a trend management expects to continue into 2026.</p>\n<h2>M&amp;A Pipeline Caution and Deal Costs</h2>\n<p>Management signaled a cautious approach to acquisitions, noting that a recent potential deal was dropped after not meeting internal criteria even after due diligence spending. The pipeline remains focused on scaled, U.S.-based brands around $100 million or more in revenue, but timing and certainty of transactions remain unclear.</p>\n<h2>Early-Stage GLP-1-Related Opportunity and Category Sensitivities</h2>\n<p>Executives flagged GLP-1 companion products as an emerging but still modest category, with early uptake encouraging yet not material to overall results. They also cited seasonal swings, including a December immunity spike, while framing GLP-1 as a possible longer-term tailwind whose impact and timing are still difficult to forecast.</p>\n<h2>Forward-Looking Guidance and Growth Outlook</h2>\n<p>For 2026, Jamieson guided consolidated revenue to $895 million–$935 million, implying 9%–14% growth, with Jamieson Brands expected to grow 9%–13% and China projected to surge another 20%–30%. Adjusted EBITDA is forecast at $174 million–$181 million and adjusted EPS at $2.08–$2.21, alongside solid cash generation before working capital and planned investments in inventory and roughly $20 million of capex.</p>\n<p>Overall, Jamieson Wellness’ call painted a picture of a growth company investing heavily but selectively in its brands, capabilities and balance sheet resilience. For investors, the message was that strong international and China-driven expansion, rising margins and disciplined capital returns outweigh near-term noise in partner revenue, working capital and deal-related costs.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Defensive-7-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/jamieson-wellness-earnings-call-signals-growth-momentum",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-28 08:15:38",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        }
    ]
}